There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Tectonic Therapeutic (TECX) and Stevanato Group (STVN) with bullish sentiments.Introducing TipRanks MCP for Agents Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools. Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.
Tectonic Therapeutic (TECX)
LifeSci Capital analyst Gaurav Maini maintained a Buy rating on Tectonic Therapeutic today and set a price target of $88.00. The company’s shares closed last Wednesday at $28.05.
According to TipRanks.com, Maini is a 2-star analyst with an average return of 3.1% and a 25.0% success rate. Maini covers the Healthcare sector, focusing on stocks such as Sionna Therapeutics, Inc., Inhibikase Therapeutics, and Liquidia Technologies.
Currently, the analyst consensus on Tectonic Therapeutic is a Strong Buy with an average price target of $80.75, implying a 188.8% upside from current levels. In a report issued on May 26, Raymond James also maintained a Buy rating on the stock with a $81.00 price target.
